Lataa...
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines–Heart Failure (GWTG-HF) Registry
IMPORTANCE: In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) tr...
Tallennettuna:
| Julkaisussa: | JAMA Cardiol |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7666432/ https://ncbi.nlm.nih.gov/pubmed/33185662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.5864 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|